HPV Genotype Distribution in Cervical Cancer and High‐Grade Lesions in Norway, and Early Vaccine Impact
International Journal of Cancer · 01.01.2027 · 160 (1) · 171-186
DOI: 10.1002/ijc.70712 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 28.08.2026. Verfasst von Terese Bekkevold und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Dysplasia. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
All cases of invasive cervical cancer (ICC) and subsets of high‐grade cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) and adenocarcinoma in situ (AIS) in Norway are tested for 37 human papillomavirus (HPV) genotypes, within a mandatory national surveillance system. We assessed the proportional attribution of HPV types in cervical lesions from predominantly unvaccinated women reported during 2017–2021 (baseline population) and the HPV type distribution by vaccination status in vaccine‐eligible cases reported during 2017–2024. Among baseline CIN2/3 cases ( n = 3087), 48% were attributable to HPV16/18, 28% to HPV31/33/45, 12% to HPV52/58 and 8% to other high‐risk types (HPV35/39/51/56/59). For AIS ( n = 550), almost all cases were attributed to HPV16/18 (91%) and HPV45 (6%). For ICC ( n = 1265), 75% were attributable to HPV16/18, 15% to HPV31/33/45, 3% to HPV52/58 and 4% to other high‐risk types. Among CIN2/3 cases born 1997 or later (eligible for vaccination at age 11–12 years, n = 154), HPV16‐attribution was higher in unvaccinated cases (49.9%, 95% CI: 33.7–66.1) than in cases vaccinated before age 15 (1.1%, 95% CI: 0–3.4). In CIN2/3 cases born 1991–1996 (eligible for catch‐up vaccination, n = 1541), HPV16‐attribution was 45.7% (95% CI: 41.9–49.7) in unvaccinated versus 35.5% (95% CI: 32.5–38.6) in vaccinated cases. Minor differences by vaccination status were observed for catch‐up‐eligible AIS ( n = 445) and ICC ( n = 135) cases. In conclusion, the baseline genotype distribution in high‐grade cervical lesions and ICC in Norway aligns with global data. Strong protection against HPV16‐induced CIN2/3 was seen in women vaccinated before age 15 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
- The Norwegian HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, Lorenskog, Norway.
- Department of Pathology, Akershus University Hospital, Lorenskog, Norway.
- Faculty of Medicine, University of Oslo, Oslo, Norway.
- Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
- Harvard T.H Chan School of Public Health, Boston, Massachusetts, USA.
ORCID-Profile: Terese Bekkevold
Zitieren
APA
Bekkevold, T., Laake, I., Feiring, B., Søreng, K., Presthus, G. K., Alfsen, G. C., Christiansen, I. K., Hansen, M., Kristiansen, H., Olsen, E., Frengen, T. G., Burger, E. A., Jonassen, C. G. M., & Trogstad, L. (2027). HPV Genotype Distribution in Cervical Cancer and High‐Grade Lesions in Norway, and Early Vaccine Impact. International Journal of Cancer, 160(1), 171-186. https://doi.org/10.1002/ijc.70712
Vancouver
Bekkevold T, Laake I, Feiring B, Søreng K, Presthus GK, Alfsen GC, et al. HPV Genotype Distribution in Cervical Cancer and High‐Grade Lesions in Norway, and Early Vaccine Impact. International Journal of Cancer. 2027;160(1):171-186. doi:10.1002/ijc.70712
BibTeX
@article{Bekkevold2027,
author = {Bekkevold, Terese and Laake, Ida and Feiring, Berit and Søreng, Kristiane and Presthus, Gro Kummeneje and Alfsen, Glenny Cecilie and Christiansen, Irene Kraus and Hansen, Mona and Kristiansen, Hanne and Olsen, Eirik and Frengen, Torstein Gjølgali and Burger, Emily A and Jonassen, Christine Genieve Monceyron and Trogstad, Lill},
title = {HPV Genotype Distribution in Cervical Cancer and High‐Grade Lesions in Norway, and Early Vaccine Impact},
journal = {International Journal of Cancer},
year = {2027},
volume = {160},
number = {1},
pages = {171--186},
doi = {10.1002/ijc.70712}
}
EUVIMED